Abryl Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
as on 11-07-2024
- Paid Up Capital ₹ 0.90 M
as on 11-07-2024
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -17.25%
(FY 2022)
- Profit 5.48%
(FY 2022)
- Ebitda -26.36%
(FY 2022)
- Net Worth 27.96%
(FY 2022)
- Total Assets -9.84%
(FY 2022)
About Abryl Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.90 M, as per Ministry of Corporate Affairs (MCA) records.
Simmi Singla and Neerja Singla serve as directors at the Company.
- CIN/LLPIN
U24239PB2006FTC030567
- Company No.
030567
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
23 Aug 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Bathinda, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Abryl Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neerja Singla  | Director | 23-Aug-2006 | Current |
| Simmi Singla | Director | 23-Aug-2006 | Current |
Financial Performance of Abryl Formulations.
Abryl Formulations Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 17.25% decrease. The company also saw a slight improvement in profitability, with a 5.48% increase in profit. The company's net worth Soared by an impressive increase of 27.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abryl Formulations?
In 2019, Abryl Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Abryl Formulations?
Unlock and access historical data on people associated with Abryl Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abryl Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abryl Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
